{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:41:20Z","timestamp":1790606480846,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.mayocp.2014.08.011","type":"journal-article","created":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T08:50:01Z","timestamp":1414831801000},"page":"1734-1739","source":"Crossref","is-referenced-by-count":14,"title":["New-Onset Heart Failure in Association With Severe Hypertension During Trastuzumab Therapy"],"prefix":"10.1016","volume":"89","author":[{"given":"Joerg","family":"Herrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tufia C.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.mayocp.2014.08.011_bib1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrcardio.2010.121","article-title":"Cardiotoxicity of anticancer treatments: what the cardiologist needs to know","volume":"7","author":"Ewer","year":"2010","journal-title":"Nat Rev Cardiol"},{"issue":"14","key":"10.1016\/j.mayocp.2014.08.011_bib2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.mayocp.2014.08.011_bib3","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","article-title":"Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31","volume":"29","author":"Perez","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2014.08.011_bib4","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1161\/CIRCULATIONAHA.107.690487","article-title":"Role of neuregulin-1\/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure","volume":"116","author":"Lemmens","year":"2007","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.mayocp.2014.08.011_bib5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/01.CIR.100.4.407","article-title":"Neuregulin in cardiac hypertrophy in rats with aortic stenosis: differential expression of erbB2 and erbB4 receptors","volume":"100","author":"Rohrbach","year":"1999","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.mayocp.2014.08.011_bib6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.mayocp.2014.08.011_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000353450","article-title":"The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population","volume":"86","author":"Adamo","year":"2014","journal-title":"Oncology"},{"issue":"2","key":"10.1016\/j.mayocp.2014.08.011_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2459\/JCM.0b013e328365afb5","article-title":"Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer","volume":"15","author":"Russo","year":"2014","journal-title":"J\u00a0Cardiovasc Med (Hagerstown)"},{"issue":"1","key":"10.1016\/j.mayocp.2014.08.011_bib9","doi-asserted-by":"crossref","first-page":"e000472","DOI":"10.1161\/JAHA.113.000472","article-title":"Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"3","author":"Ezaz","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.mayocp.2014.08.011_bib10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/jch.12058","article-title":"Patients with hypertensive crises who are admitted to a coronary care unit: clinical characteristics and outcomes","volume":"15","author":"Gonz\u00e1lez Pacheco","year":"2013","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"issue":"4","key":"10.1016\/j.mayocp.2014.08.011_bib11","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/eurheartj\/ehi044","article-title":"Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology","volume":"26","author":"Nieminen","year":"2005","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.mayocp.2014.08.011_bib12","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"31","key":"10.1016\/j.mayocp.2014.08.011_bib13","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.mayocp.2014.08.011_bib14","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.mayocp.2014.08.011_bib15","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1470-2045(11)70033-X","article-title":"Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial","volume":"12","author":"Gianni","year":"2011","journal-title":"Lancet Oncol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619614007459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619614007459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T22:25:53Z","timestamp":1538087153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619614007459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0025619614007459"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2014.08.011","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}